tucidinostat tucidinostat tucidinostat (inn, also known as chidamide and sold under the brand names epidaza and hiyasta) is a histone deacetylase inhibitor (hdi) developed in china. it was also known as hbi-8000. it is a benzamide hdi and inhibits class i hdac1, hdac2, hdac3, as well as class iib hdac10. tucidinostatclinical datatrade namesepidaza, hiyastaother nameschidamide, hbi-8000identifiers iupac name n-(2-amino-4-fluorophenyl)-4-amino]methyl]benzamide cas number1616493-44-7 ypubchem cid12136798drugbank06334chemspider7976319unii87cic980y0keggd10993chemblchembl3621988chemical and physical dataformulac22h19fn4o2molar mass390.418 g·mol−13d model (jsmol)interactive image smiles c1=cc(=cn=c1)/c=c/c(=o)ncc2=cc=c(c=c2)c(=o)nc3=c(c=c(c=c3)f)n inchi inchi=1s/c22h19fn4o2/c23-18-8-9-20(19(24)12-18)27-22(29)17-6-3-16(4-7-17)14-26-21(28)10-5-15-2-1-11-25-13-15/h1-13h,14,24h2,(h,26,28)(h,27,29)/b10-5+key:szmjvtadhfnais-bjmvgyqfsa-n tucidinostat is approved by the chinese fda for relapsed or refractory peripheral t-cell lymphoma (ptcl) and has orphan drug status in japan. in japan, it was approved for relapsed or refractory adult t-cell leukemia-lymphoma (atll) treatment in june 2021. tucidinostat is being researched as a treatment for pancreatic cancer. however, it is not us fda approved for the treatment of pancreatic cancer.